It looks like nothing was found at this location. Maybe try one of the links below or a search?
Popular Articles:
-
Response to EPO consultation: Don’t impose oral proceedings by videoconference
-
Quality at the EPO – One Modest and one Serious Proposal
-
‘Opposition against Unitary Patent comes from fearful lawyers and critics who only have a theoretical interest’
-
Leading German patent law firms criticize European Patent Office
-
UPC: four reasons on why the PPA is not legally in force
-
The EPO’s Vision (V) – Trust
Recent Articles:
-
Announcement of the national program “MOVER” raises expectations for an increase in patent filings for green technology
-
UPC “saisie-contrefaçon” Part III: the “C-Kore” case
-
Brazil: Animal Health and Patent Litigation
-
China’s Supreme People Court decides FRAND dispute in ACT v Oppo
-
UPC “saisie-contrefaçon” Part II: the “OERLIKON” case
-
UPC “saisie-contrefaçon” Part I: the texts
Random Articles:
-
Germany’s Federal Court of Justice revokes Leo’s Calcipotriol Monohydrate Patent
-
Patent case: Nokia Solutions and Networks OY vs. Oleading B.V. and Reflection Investment B.V., Netherlands
-
Drawings cannot be used to limit scope of protection
-
On police seizures
-
How limited are the legislative powers of the EPO Administrative Council?
-
UK Government guidance on Unitary Patent system in case there is no Brexit deal
-
NL – Second Medical Use – Too little, too late
-
Zeitversetztes Fernsehen, Court of Appeal Duesseldorf (Oberlandesgericht Duesseldorf), 14 January 2009
-
(Indirect) infringement, Antibodies, Biologics, Extension of subject matter, Inventive step, Pharma, Revocation, Scope of protection, Sufficiency of disclosure, United Kingdom, Validity
Regeneron Pharmaceuticals Inc v (1) Kymab Ltd (2) Novo Nordisk A/S
-
Many Antagonisms, No Simple Solutions: International Enforcement of Standard Essential Patents